Deregulation of Rho GTPases in cancer.
| dc.contributor.author | Porter, Andrew P | |
| dc.contributor.author | Papaioannou, Alexandra | |
| dc.contributor.author | Malliri, Angeliki | |
| dc.date.accessioned | 2016-05-25T15:27:16Z | en |
| dc.date.available | 2016-05-25T15:27:16Z | en |
| dc.date.issued | 2016-04-22 | en |
| dc.identifier.citation | Deregulation of Rho GTPases in cancer. 2016:1-16 Small GTPases | en |
| dc.identifier.issn | 2154-1256 | en |
| dc.identifier.pmid | 27104658 | en |
| dc.identifier.doi | 10.1080/21541248.2016.1173767 | en |
| dc.identifier.uri | http://hdl.handle.net/10541/610719 | en |
| dc.description.abstract | In vitro and in vivo studies and evidence from human tumors have long implicated Rho GTPase signaling in the formation and dissemination of a range of cancers. Recently next generation sequencing has identified direct mutations of Rho GTPases in human cancers. Moreover, the effects of ablating genes encoding Rho GTPases and their regulators in mouse models, or through pharmacological inhibition, strongly suggests that targeting Rho GTPase signaling could constitute an effective treatment. In this review we will explore the various ways in which Rho signaling can be deregulated in human cancers. | |
| dc.language | ENG | en |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to Small GTPases | en |
| dc.title | Deregulation of Rho GTPases in cancer. | en |
| dc.type | Article | en |
| dc.contributor.department | Cell Signaling Group, Cancer Research UK Manchester Institute, The University of Manchester , Manchester , UK | en |
| dc.identifier.journal | Small GTPases | en |
| html.description.abstract | In vitro and in vivo studies and evidence from human tumors have long implicated Rho GTPase signaling in the formation and dissemination of a range of cancers. Recently next generation sequencing has identified direct mutations of Rho GTPases in human cancers. Moreover, the effects of ablating genes encoding Rho GTPases and their regulators in mouse models, or through pharmacological inhibition, strongly suggests that targeting Rho GTPase signaling could constitute an effective treatment. In this review we will explore the various ways in which Rho signaling can be deregulated in human cancers. |